- Trials with a EudraCT protocol (139)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
		
	   		
	   		    
                    
                   	
                   	    139 result(s) found for: Health crisis.
                    
                
			
   			
		
		Displaying page 1 of 7.
	
	
	| EudraCT Number: 2012-004892-37 | Sponsor Protocol Number: NL41205.018.12 | Start Date*: 2013-03-21 | |||||||||||
| Sponsor Name:Academic Medical Center | |||||||||||||
| Full Title: N-Acetylcysteine in patients with Sickle Cell Disease: Reducing the incidence of daily life pain in patients with sickle cell disease | |||||||||||||
| Medical condition: Sickle Cell | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004674-34 | Sponsor Protocol Number: P16/23 | Start Date*: 2018-09-25 | 
| Sponsor Name:CENTRE HOSPITALIER DE VERSAILLES | ||
| Full Title: OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS | ||
| Medical condition: CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-016996-31 | Sponsor Protocol Number: P09-004 | Start Date*: 2010-06-28 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Upsher-Smith Laboratories, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-O... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Refractory partial-onset seizures with or without secondary generalization | ||||||||||||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2006-005722-23 | Sponsor Protocol Number: N01274 | Start Date*: 2007-05-15 | |||||||||||
| Sponsor Name:UCB Pharma S.A. | |||||||||||||
| Full Title: Open-label, single-arm, multi-center, pharmacokinetic, safety and tolerability study of levetiracetam intravenous infusion in children (4 - 16 years old) with epilepsy. | |||||||||||||
| Medical condition: Epilepsy | |||||||||||||
| 
 | |||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-017904-95 | Sponsor Protocol Number: P09-005 | Start Date*: 2010-06-28 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Upsher-Smith Laboratories, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures who had Participated in P09-004, a Randomized, Multicenter, Doub... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Refractory partial-onset seizures with or without secondary generalization | ||||||||||||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-018766-23 | Sponsor Protocol Number: CBGG492A2211 | Start Date*: 2010-06-28 | |||||||||||
| Sponsor Name:Novartis Farmacéutica S.A | |||||||||||||
| Full Title: Estudio aleatorizado, a doble ciego, controlado con placebo, exploratorio, con ajuste de dosis, de 12 semanas de seguimiento para evaluar la actividad antiepiléptica de BGG492 administrado por vía... | |||||||||||||
| Medical condition: epilepsia | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) LT (Prematurely Ended) BE (Completed) AT (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-004467-19 | Sponsor Protocol Number: CAMN107AHU01 | Start Date*: 2008-08-13 | 
| Sponsor Name:Novartis Hungary Ltd | ||
| Full Title: An open-label, single center study of oral AMN 107 (nilotinib) in adult patients with imatinib - resistant or - intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast cri... | ||
| Medical condition: adult patients with imatinib - resistant or - intolerant CML-CP, CML-AP or CML-BC | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-001458-22 | Sponsor Protocol Number: A0081157 | Start Date*: 2007-07-31 | |||||||||||
| Sponsor Name:PFIZER | |||||||||||||
| Full Title: "ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, MULTICÉNTRICO, CON DOSIS FLEXIBLES, COMPARATIVO DE PREGABALINA Y LEVETIRACETAM COMO TRATAMIENTO ADYUVANTE PARA REDUCIR LA FRECUENCIA DE LAS ... | |||||||||||||
| Medical condition: Tratamiento adyuvante de las crisis epilépticas parciales, con o sin generalización secundaria. | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) GR (Completed) DE (Prematurely Ended) BE (Completed) FR (Completed) CZ (Completed) IT (Completed) LT (Completed) SI (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-020871-22 | Sponsor Protocol Number: AGG-901 | Start Date*: 2011-02-02 | |||||||||||
| Sponsor Name:West-ward Pharmaceutical Corporation | |||||||||||||
| Full Title: An international, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of phenobarbital as adjunctive therapy in participants (≥ 17 to 70 years ... | |||||||||||||
| Medical condition: Epilepsy with partial onset seizures (complex or simple with motor symptoms only) whether or not secondarily generalized. | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004511-27 | Sponsor Protocol Number: S64647 | Start Date*: 2021-08-05 | |||||||||||
| Sponsor Name:University Hospital Leuven | |||||||||||||
| Full Title: Add-on clioquinol in drug-resistant childhood epilepsy: an exploratory study | |||||||||||||
| Medical condition: Drug resistant epilepsy in children | |||||||||||||
| 
 | |||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004114-42 | Sponsor Protocol Number: | Start Date*: 2011-08-26 | |||||||||||
| Sponsor Name:University Hospital Antwerp | |||||||||||||
| Full Title: Fenfluramine as anti-epilepticum in Dravet syndrome. | |||||||||||||
| Medical condition: Fenfluramine is an amphetamine which was in the past used as anorexigan. Their are a few publications of effectivness of this medication in epilepsy.We want to investigate was is the exact place of... | |||||||||||||
| 
 | |||||||||||||
| Population Age: Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-003961-49 | Sponsor Protocol Number: P261-301 | Start Date*: 2015-03-03 | |||||||||||
| Sponsor Name:Upsher-Smith Laboratories, Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity i... | |||||||||||||
| Medical condition: Epilepsy | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) CZ (Completed) IT (Completed) DE (Completed) ES (Completed) AT (Completed) LT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003664-29 | Sponsor Protocol Number: EP0156 | Start Date*: 2021-04-30 | |||||||||||
| Sponsor Name:UCB Biopharma SRL | |||||||||||||
| Full Title: Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy | |||||||||||||
| Medical condition: Epilepsy | |||||||||||||
| 
 | |||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) IE (Completed) HU (Completed) PL (Completed) CZ (Completed) BE (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-000173-29 | Sponsor Protocol Number: N01237 | Start Date*: 2006-04-13 | |||||||||||
| Sponsor Name:UCB S.A. (Global Medical Affairs) | |||||||||||||
| Full Title: A multicenter, open-label single-arm follow-up trial evaluating the long-term safety of levetiracetam, for patients suffering from epilepsy and coming from the study N01175. | |||||||||||||
| Medical condition: Epilepsy | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-001433-98 | Sponsor Protocol Number: N01315 | Start Date*: 2008-08-11 | |||||||||||
| Sponsor Name:UCB BioSciences, Inc | |||||||||||||
| Full Title: An open-label, multinational, multicenter, follow-up study to evaluate the long-term safety and efficacy of brivaracetam, used at a flexible dose up to a maximum of 200 mg/day, in subjects aged 16 ... | |||||||||||||
| Medical condition: Epilepsy | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) CZ (Completed) SE (Completed) ES (Completed) FR (Completed) HU (Completed) FI (Prematurely Ended) IT (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-006344-59 | Sponsor Protocol Number: N01252 | Start Date*: 2007-06-07 | |||||||||||
| Sponsor Name:UCB Pharma S.A. | |||||||||||||
| Full Title: A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seiz... | |||||||||||||
| Medical condition: Partial Onset Seizures | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) NL (Completed) FR (Completed) GB (Completed) HU (Completed) FI (Completed) IT (Completed) DE (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003698-24 | Sponsor Protocol Number: 40411813EPY2001 | Start Date*: 2021-06-10 | ||||||||||||||||
| Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects with Focal Ons... | ||||||||||||||||||
| Medical condition: Focal Onset Seizures | ||||||||||||||||||
| 
 | ||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) PL (Completed) ES (Ongoing) BE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-004714-27 | Sponsor Protocol Number: N01258 | Start Date*: 2011-10-05 | |||||||||||
| Sponsor Name:UCB Biosciences, Inc. | |||||||||||||
| Full Title: A Multicenter, Open-label, Four-arm, Randomized trial, Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepilep... | |||||||||||||
| Medical condition: Epilepsy | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-004265-12 | Sponsor Protocol Number: NBI-921352-FOS2022 | Start Date*: 2021-12-21 | |||||||||||
| Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
| Full Title: Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with Focal Onset Seizures (FOS) | |||||||||||||
| Medical condition: Focal Onset Seizures (FOS) | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) FR (Completed) HU (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002986-21 | Sponsor Protocol Number: MST-188-01 | Start Date*: 2014-06-16 | |||||||||||
| Sponsor Name:Mast Therapeutics, Inc. | |||||||||||||
| Full Title: Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial of MST-188 (purified ... | |||||||||||||
| Medical condition: Sickle Cell Disease with Vaso-Occlusive Crisis | |||||||||||||
| 
 | |||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
 .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
 Query did not match any studies.
    	Query did not match any studies.
     
				
